

VACCINE	VACCINATION SCHEDULE	MAJOR INDICATIONS	CONTRAINDICATIONS AND PRECAUTIONS
<p><b>Serogroup B Meningococcal Vaccines</b></p> <p>- <i>MenB-4C (Bexsero®</i>, 2 dose series)</p> <p>- <i>MenB-FHbp (Trumenba®</i>, 3 dose series)</p>	<p>For MenB-4C: 0–2 months</p> <p>For MenB-FHbp: 0–2–6 months</p>	<p><b>Category A: Should be administered to:*</b></p> <p>Persons at increased risk due to</p> <ul style="list-style-type: none"> <li>• Outbreaks of serogroup B meningococcal disease</li> <li>• Persistent complement component deficiencies</li> <li>• Treatment with eculizumab for hemolytic uremic syndrome or paroxysmal nocturnal hemoglobinuria</li> <li>• Anatomic or functional asplenia including sickle cell disease</li> </ul> <p>Laboratory workers routinely exposed to isolates of <i>N. meningitis</i></p> <p><b>Category B: May be administered to:**</b></p> <p>Adolescents and young adults 16–23 for short term protection (preferred age 16–18)</p> <p>Serogroup B vaccines may be administered with Men ACW but at different anatomic site, if possible.</p> <p>Defer in pregnant or lactating females unless at increased risk.</p>	<p>Defer in pregnant or lactating females unless at increased risk.</p> <p>History of hypersensitivity to any of the components of the vaccine.</p> <p>Bexsero®: use with caution if hypersensitive to latex.</p> <p>The two vaccines are not interchangeable, so the same product must be used for all doses.</p>

\*Category A: Recommendations made for all persons in age or risk-factor group.

\*\*Category B: Recommendations are made using individual clinical decision-making

**Other recommendations:**

Immunization requirements and recommendations for international travel may vary, depending on personal medical history and travel destination. Anyone anticipating international travel should contact a health care provider for specific information.

Prepared by ACHA's Vaccine-Preventable Diseases Advisory Committee

